Sugi Predict

Sugi Predict / Compounds / SCHEMBL16295010

SCHEMBL16295010

SCHEMBL16295010

O=C(O)c1ncsc1NS(=O)(=O)Cc1ccccc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ HTR1A P08908 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR1F P30939 1/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ NR1I2 O75469 1/20 0.32
▸ TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30560816 1.00 KDM4E (0.40) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30560867 0.85 KDM4E (0.40) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL30560812 0.85 KDM4E (0.40) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL16295032 0.85 KDM4E (0.53) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL16295958 0.85 MEN1 (0.43) KDM4EALDH1A1MAPT
SCHEMBL16296075 0.85 KDM4E (0.40) KDM4ECYP1A2HPGDALDH1A1SMN1; SMN2
SCHEMBL16296220 0.85 KDM4E (0.40) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL16296111 0.85 KDM4E (0.40) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL30560887 0.85 MEN1 (0.43) KDM4EALDH1A1MAPT
SCHEMBL16311105 0.84 KDM4E (0.46) KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 — — EP claimed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 — — US claimed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 — — US claimed
EP-3008045-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS Antabio SAS (FR) 2016-04-20 — — EP claimed
WO-2014198849-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2014-12-18 — — WO claimed
US-12378244-B2 Diazabicyclooctanones as inhibitors of serine β-lactamases ANTABIO SAS (FR) 2025-08-05 — — US disclosed
US-20240391919-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2024-11-28 — — US disclosed
US-11905286-B2 Diazabicyclooctanones as inhibitors of serine beta-lactamases ANTABIO SAS (FR) 2024-02-20 — — US disclosed
CN-117384155-A Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2024-01-12 — — CN disclosed
EP-4272831-A2 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES Antabio SAS (FR) 2023-11-08 — — EP disclosed
CN-111954671-B Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2023-09-01 — — CN disclosed
EP-3833665-B1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2023-07-19 — — EP disclosed
EP-3833665-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES Antabio SAS (FR) 2021-06-16 — — EP disclosed
CN-111954671-A Diazabicyclooctanones as serine beta-lactamase inhibitors 安塔比奥公司 2020-11-17 — — CN disclosed
WO-2020030761-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES ANTABIO SAS (FR) 2020-02-13 — — WO disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 — — EP disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 — — US disclosed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 — — US disclosed
EP-3008045-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS Antabio SAS (FR) 2016-04-20 — — EP disclosed
WO-2014198849-A1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11905286-B2 Diazabicyclooctanones as inhibitors of serine beta-lactamases STS, BCKDK, PEPD KDM4E 1255/4885CYP1A2 1553/4885CYP2D6 548/4885
US-20240391919-A1 DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES STS, BCKDK, PEPD KDM4E 1255/4885CYP1A2 1553/4885CYP2D6 548/4885
US-12378244-B2 Diazabicyclooctanones as inhibitors of serine β-lactamases STS, PEPD, BCKDK KDM4E 1152/4885CYP1A2 1499/4885CYP2D6 495/4885
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ME1, TALDO1, COASY KDM4E 3604/4885CYP1A2 606/4885CYP2D6 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.